A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group.
about
CMV in Hematopoietic Stem Cell TransplantationCurrent and potential treatments for ubiquitous but neglected herpesvirus infectionsGuidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspectiveA prospective study comparing quantitative Cytomegalovirus (CMV) polymerase chain reaction in plasma and pp65 antigenemia assay in monitoring patients after allogeneic stem cell transplantationCan low-dose preemptive valganciclovir replace standard intravenous ganciclovir treatment in recipients of allogeneic stem cell transplantation?Viral pneumonias. Infection in the immunocompromised host.Evaluation of new quantitative assays for diagnosis and monitoring of cytomegalovirus disease in human immunodeficiency virus-positive patientsHuman cytomegalovirus immediate-early mRNA detection by nucleic acid sequence-based amplification as a new parameter for preemptive therapy in bone marrow transplant recipientsReal-time automated PCR for early diagnosis and monitoring of cytomegalovirus infection after bone marrow transplantation.Quantification of human cytomegalovirus DNA in bone marrow transplant recipients by real-time PCR.Foscarnet in the management of cytomegalovirus infections in hematopoietic stem cell transplant patients.The costs and cost-effectiveness of allogeneic peripheral blood stem cell transplantation versus bone marrow transplantation in pediatric patients with acute leukemiaProphylaxis for CMV should now replace pre-emptive therapy in solid organ transplantation.Opportunistic infections after blood and marrow transplantation.Preventing opportunistic infections in bone marrow transplant recipients.Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy.Prevention and treatment of cytomegalovirus infection in organ transplant recipients.Molecular methods for cytomegalovirus surveillance in bone marrow transplant recipients.Oral valganciclovir: a new option for treatment of cytomegalovirus infection and disease in immunocompromised hosts.Expert opinion on pharmacotherapy of kidney disease in HIV-infected patients.Prevention and management of CMV-related problems after hematopoietic stem cell transplantation.Prevalence of invasive cytomegalovirus disease with administration of muromonab CD-3 in patients undergoing orthotopic liver transplantation.Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplantsHigh levels of circulating cytomegalovirus DNA reflect visceral organ disease in viremic immunosuppressed patients other than marrow recipients.Idiopathic pneumonia syndrome after hematopoietic cell transplantation: evidence of occult infectious etiologiesPulmonary complications of solid organ and hematopoietic stem cell transplantation.Valganciclovir: oral prevention and treatment of cytomegalovirus in the immunocompromised host.Ganciclovir prophylaxis decreases frequency and severity of cytomegalovirus disease in seropositive liver transplant recipients treated with OKT3 monoclonal antibodies.Cytomegalovirus in hematopoietic stem cell transplant recipientsEmerging therapies for herpes viral infections (types 1 - 8).Human cytomegalovirus-specific T-cell immune reconstitution in preemptively treated heart transplant recipients identifies subjects at critical risk for infectionHuman cytomegalovirus in a SCID-hu mouse: thymic epithelial cells are prominent targets of viral replication.Antiviral therapy: current concepts and practicesAddressing viral resistance through vaccinesEvaluation of pulmonary infiltrates in patients after stem cell transplantation.Antiretroviral therapy and the kidney: balancing benefit and risk in patients with HIV infection.Early detection of human cytomegalovirus viremia in bone marrow transplant recipients by DNA amplification.Monitoring of leukocyte cytomegalovirus DNA in bone marrow transplant recipients by nested PCR.Monitoring of cytomegalovirus infection and disease in bone marrow recipients by reverse transcription-PCR and comparison with PCR and blood and urine culturesEvaluation of a quantitative plasma PCR plate assay for detecting cytomegalovirus infection in marrow transplant recipients.
P2860
Q26740385-7A946D4D-8C5A-45B8-BFC7-96DA53DA1F1DQ27023452-06574595-32D0-4A7D-8F7C-CE62D59B339DQ28388806-0E55D30D-19A1-4C46-8BDC-FBA984EE1DCEQ33264234-E7DF5911-97E2-49A1-B8CB-88FF8D75FE91Q33410582-E83D8BDA-6DDA-4499-B14F-7BB2D32779D6Q33846623-8CEB99E9-79B1-49BB-A34F-BC2403081123Q33962859-9B0E74CE-4F82-4F39-B175-B691F338780DQ33966910-3F99C4C7-73EC-4023-B478-25C1B9308C49Q33968089-84079FC4-669D-4DE9-9514-1165331FA6C3Q33974273-0C29F614-9888-4601-8AC9-52422CDC0BFCQ34034462-FD351168-DE08-4CEF-838D-921BE21B0885Q34057955-31FBF3EC-A0EC-4E15-8215-C443F576F6A5Q34191785-6E781F46-5E2E-4D88-AEEF-D6DFB3EF5347Q34294774-41F9025F-D867-481D-82DC-7B3D687C0D6FQ34294792-6A2E46A2-1C87-4B8D-BB5A-8555C6F44E8AQ34294838-4F2E3AA7-9198-45B1-AA48-A8F5EEC0B56EQ34294851-4AA8063D-68EF-41D8-AB61-A8CBD89FA6C7Q34439235-1EE8EC9E-3F65-4747-850F-0CE3B48C00BCQ34481742-63920E07-067B-495C-9062-B08296B94D3FQ34686870-65AA4006-C8BD-49D6-9F56-3C98EDCF7EE4Q34785629-D66AC61B-8AE5-4974-8159-9BFF218EBEBFQ35228506-CECEC71A-A29F-4ECE-9246-80D42B5F46F4Q35558815-23AEC849-7F1B-4470-A6B7-D2726C418299Q35608425-C9C67646-6E89-4F27-A54A-A2E6C005D98DQ35724040-8172ACBB-32C8-4431-9263-42477E83064AQ35740698-5BC3D540-CE17-4171-8FD0-881957CFCAF7Q35871893-0D1861BC-562E-4318-B4DA-C92F6149C922Q35900369-5F9C851A-C58C-4E65-A915-B24C929AAE9BQ35922928-871F706C-76F1-46E6-80B1-FCF54B2B9A29Q35967376-57C4865C-15D8-4BCF-8F2F-07932D55B2F7Q36023008-5D29205A-8175-4D1F-AFE4-93B700B51DD4Q36030112-4357DBF3-B5D6-45C7-B4E8-0DB8BC0A2EDCQ36070394-8EA1F41B-2EE1-4CFF-BA0C-B8FB3EA348ECQ36304783-0DD05D94-D3F3-48F4-9E5E-DD8C2015E5D2Q36328397-4081DD5B-E927-4489-B11D-881724332A14Q36407276-FF7CE204-572F-4611-833A-2F98F767F5B9Q36521918-EC75532B-41FE-48AA-869F-C84A10287C51Q36525203-82C3B745-6033-44A1-A742-B06C92D1E2B6Q36537494-ECBF14EB-7E6A-4C4F-AE24-454DACB98B23Q36543781-3D6B0971-865E-4E2C-A455-0374D308EC15
P2860
A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh-hant
name
A randomized, controlled trial ...... anford-Syntex CMV Study Group.
@en
A randomized, controlled trial ...... anford-Syntex CMV Study Group.
@nl
type
label
A randomized, controlled trial ...... anford-Syntex CMV Study Group.
@en
A randomized, controlled trial ...... anford-Syntex CMV Study Group.
@nl
prefLabel
A randomized, controlled trial ...... anford-Syntex CMV Study Group.
@en
A randomized, controlled trial ...... anford-Syntex CMV Study Group.
@nl
P2093
P1476
A randomized, controlled trial ...... anford-Syntex CMV Study Group.
@en
P2093
P304
P356
10.1056/NEJM199104113241501
P407
P577
1991-04-01T00:00:00Z